Sichuan Kelun Pharmaceutical Co Ltd (002422):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Sichuan Kelun Pharmaceutical Co Ltd (002422) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8094
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:中国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Sichuan Kelun Pharmaceutical Co., Ltd. (Kelun) is engaged in manufacturing and distribution of IV Solutions. The company’s products portfolio includes glucose injection, sodium chloride injection, glucose and sodium chloride injection, ringer’s injection, lactated ringer’s injection, compound amino acid injection, alanyl glutamine injection, compound amino acids, fat emulsion injection, vitamin c and glucose injection, vitamin c and sodium chloride injection, among others. It also offers products to serve parenteral nutrition, digestive system, cardiovascular, antipsychotic, respiratory system, anti-pathogenic microorganisms, and APIs and intermediates. The company is also involved in research and development of pharmaceutical products. Kelun is headquartered in Chengdu, Sichuan, China.

Sichuan Kelun Pharmaceutical Co Ltd (002422) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Sichuan Kelun Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 12
Debt Offering 12
Sichuan Kelun Pharma to Raise USD63.3 Million in Private Placement of Bonds Due 2018 12
Sichuan Kelun Pharma Raises USD111.2 Million in Public Offering of 5.65% 2018 Second Tranche Notes 13
Sichuan Kelun Pharma Raises USD79 Million in Public Offering of 6.2% 2018 First Tranche Notes Due 2021 14
Sichuan Kelun Pharma Raises USD210 Million in First Tranche of Public Offering of 5.38% Notes Due 2020 15
Sichuan Kelun Pharma Raises USD206.9 Million in Second Tranche of Public Offering 16
Sichuan Kelun Pharma Raises USD88.6 Million in Public Offering of 5.38% Bonds Due 2020 17
Sichuan Kelun Pharma Raises USD58 Million in Public Offering of 4.89% Bonds Due 2022 18
Sichuan Kelun Pharma Raises USD72.7 Million in Public Offering of Bonds 19
Sichuan Kelun Pharma Completes Public Offering Of Bonds Due 2018 For US$175 Million 20
Sichuan Kelun Pharma Completes Public Offering Of Bonds Due 2017 For US$238 Million 21
Sichuan Kelun Pharma Announces Debt Offering Of Notes Due 2017 For US$412 Million 22
Acquisition 23
Sichuan Kelun Pharma to Acquire Xinjiang-Based Biomedicine company for USD3 Million 23
Sichuan Kelun Pharma Plans to Acquire 35% stake in Changshu-Based Biotechnology Company 24
Sichuan Kelun Pharma Plans to Acquire Remaining 20% stake in Guangxi-Based Pharmaceutical Unit for USD5.3 Million 25
Sichuan Kelun Pharma Acquires KLUS Pharma for USD13 Million 26
Sichuan Kelun Pharma to Acquire 80% Stake in Biotechnology Company 27
Sichuan Kelun Pharma Plans to Acquire Remaining 15% Stake in Zhejiang-based pharmaceutical unit 28
Sichuan Kelun Pharma Acquires Guizhou Kelun Pharma, Pharmaceutical Preparations Manufacturer 29
Sichuan Kelun Pharma Acquires 56% Stake In Chengdu Pharma Company For US$32.8 Million 30
Sichuan Kelun Pharmaceutical Co Ltd – Key Competitors 31
Sichuan Kelun Pharmaceutical Co Ltd – Key Employees 32
Sichuan Kelun Pharmaceutical Co Ltd – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Affiliate 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sichuan Kelun Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Sichuan Kelun Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Sichuan Kelun Pharma to Raise USD63.3 Million in Private Placement of Bonds Due 2018 12
Sichuan Kelun Pharma Raises USD111.2 Million in Public Offering of 5.65% 2018 Second Tranche Notes 13
Sichuan Kelun Pharma Raises USD79 Million in Public Offering of 6.2% 2018 First Tranche Notes Due 2021 14
Sichuan Kelun Pharma Raises USD210 Million in First Tranche of Public Offering of 5.38% Notes Due 2020 15
Sichuan Kelun Pharma Raises USD206.9 Million in Second Tranche of Public Offering 16
Sichuan Kelun Pharma Raises USD88.6 Million in Public Offering of 5.38% Bonds Due 2020 17
Sichuan Kelun Pharma Raises USD58 Million in Public Offering of 4.89% Bonds Due 2022 18
Sichuan Kelun Pharma Raises USD72.7 Million in Public Offering of Bonds 19
Sichuan Kelun Pharma Completes Public Offering Of Bonds Due 2018 For US$175 Million 20
Sichuan Kelun Pharma Completes Public Offering Of Bonds Due 2017 For US$238 Million 21
Sichuan Kelun Pharma Announces Debt Offering Of Notes Due 2017 For US$412 Million 22
Sichuan Kelun Pharma to Acquire Xinjiang-Based Biomedicine company for USD3 Million 23
Sichuan Kelun Pharma Plans to Acquire 35% stake in Changshu-Based Biotechnology Company 24
Sichuan Kelun Pharma Plans to Acquire Remaining 20% stake in Guangxi-Based Pharmaceutical Unit for USD5.3 Million 25
Sichuan Kelun Pharma Acquires KLUS Pharma for USD13 Million 26
Sichuan Kelun Pharma to Acquire 80% Stake in Biotechnology Company 27
Sichuan Kelun Pharma Plans to Acquire Remaining 15% Stake in Zhejiang-based pharmaceutical unit 28
Sichuan Kelun Pharma Acquires Guizhou Kelun Pharma, Pharmaceutical Preparations Manufacturer 29
Sichuan Kelun Pharma Acquires 56% Stake In Chengdu Pharma Company For US$32.8 Million 30
Sichuan Kelun Pharmaceutical Co Ltd, Key Competitors 31
Sichuan Kelun Pharmaceutical Co Ltd, Key Employees 32
Sichuan Kelun Pharmaceutical Co Ltd, Subsidiaries 33
Sichuan Kelun Pharmaceutical Co Ltd, Affiliate 34

List of Figures
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sichuan Kelun Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Sichuan Kelun Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Sichuan Kelun Pharmaceutical Co Ltd (002422):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bonduelle Sca
    Bonduelle Sca - Strategy, SWOT and Corporate Finance Report Summary Bonduelle Sca - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Immunovia AB (IMMNOV):企業の製品パイプライン分析
    Summary Immunovia AB (Immunovia) is a molecular diagnostics company that offers clinical testing for early diagnosis of pancreatic cancer. The company develops IMMray, a technology platform based on antibody microarray analysis, which can be used in the early diagnosis of cancer, predicting disease …
  • Dauntless Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Dauntless Pharmaceuticals Inc (Dauntless) is a biotech company that develops therapeutic agents. The company’s pipeline product include DP1038, a therapeutic agent used for the treatment of endocrine cancers. It operates through various stages of development. Dauntless manages the developmen …
  • Skanska AB (SKA B):企業の財務・戦略的SWOT分析
    Skanska AB (SKA B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Cantargia AB (CANTA):製薬・医療:M&Aディール及び事業提携情報
    Summary Cantargia AB (Cantargia), a subsidiary of Lund University Bioscience AB is a biotechnology company that develops antibody based cancer treatments. The company’s product candidate CAN04 is used for the treatment of several cancers including non-small cell lung cancer and pancreatic cancer. It …
  • Canadian Zinc Corp.:企業の戦略・SWOT・財務情報
    Canadian Zinc Corp. - Strategy, SWOT and Corporate Finance Report Summary Canadian Zinc Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Synexus Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Synexus Ltd (Synexus), a subsidiary of Synexus Clinical Research Limited, is a site management organisation that offers patient recruitment and trial management services. The company services include feasibility assessment, project management, patient engagement, patient-centric clinical tri …
  • Anavex Life Sciences Corp (AVXL):製薬・医療:M&Aディール及び事業提携情報
    Summary Anavex Life Sciences Corp (Anavex) is a clinical-stage biopharmaceutical company that focuses on developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, other central nervous system (CNS) diseases, pain and various types of cancer. The c …
  • Biohit Oyj (BIOBV):企業の財務・戦略的SWOT分析
    Summary Biohit Oyj (Biohit) is a biotechnology company that offers research and early diagnosis processing products. The company’s products comprise acetaldehyde binding products, diagnostic tests, dysbiosis test, microplate readers and washers, monoclonal antibodies, and pipettes. It targets therap …
  • Chrono Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Chrono Therapeutics Inc (CTI) is a personalized medicine manufacturer that provides programmable passive transdermal drug delivery products. The company provides smartstop, a programmable smoking cessation therapy that helps people to quit smoking and improve cessation outcomes. Its wearable …
  • First Quantum Minerals Ltd:戦略・SWOT・企業財務分析
    First Quantum Minerals Ltd - Strategy, SWOT and Corporate Finance Report Summary First Quantum Minerals Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Lepu Medical Technology (Beijing) Co Ltd (300003):医療機器:M&Aディール及び事業提携情報
    Summary Lepu Medical Technology (Beijing) Co Ltd (Lepu Medical) is a medical technology company that offers medical equipments, pharmaceutical products and healthcare services. The company’s products include cardiovascular interventional products, surgical cardiology products, peripheral interventio …
  • Aeon Co., Ltd.:企業の戦略・SWOT・財務情報
    Aeon Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Aeon Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Oaks Hotels & Resorts Limited
    Oaks Hotels & Resorts Limited - Strategy, SWOT and Corporate Finance Report Summary Oaks Hotels & Resorts Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Northwest Pipe Co (NWPX):企業の財務・戦略的SWOT分析
    Northwest Pipe Co (NWPX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Barclaycard:企業の戦略・SWOT・財務情報
    Barclaycard - Strategy, SWOT and Corporate Finance Report Summary Barclaycard - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Amicus Therapeutics Inc (FOLD):製薬・医療:M&Aディール及び事業提携情報
    Summary Amicus Therapeutics Inc (Amicus Therapeutics) is a biotechnology company that focuses on the research, development and commercialization of small molecules drugs and orally administered drugs known as pharmacological chaperones for the treatment of rare and orphan diseases. The company's lea …
  • Approach Resources Inc (AREXQ):企業の財務・戦略的SWOT分析
    Approach Resources Inc (AREXQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Electricite de France SA:企業の戦略・SWOT・財務情報
    Electricite de France SA - Strategy, SWOT and Corporate Finance Report Summary Electricite de France SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Premier Gold Mines Limited:企業のM&A・事業提携・投資動向
    Premier Gold Mines Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Premier Gold Mines Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆